Pancreatic Cancer Diagnostic Kit Using CFB and CA 19-9 Antibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for pancreatic cancer lack effective early detection tools, leading to late-stage diagnoses and poor survival rates due to the low specificity and sensitivity of existing markers like CA 19-9, which are also elevated in other diseases, making it difficult to accurately diagnose pancreatic cancer at an early stage.
Innovation Solution
A diagnostic kit utilizing antibodies specifically binding to complement factor B (CFB) and carbohydrate antigen 19-9 (CA 19-9) proteins, allowing for the measurement of protein expression levels in blood samples to detect pancreatic cancer, with CFB serving as a novel biomarker for enhanced specificity and sensitivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CA 19-9 is used as a tumor marker for pancreatic cancer diagnosis, then the diagnosis can be performed, but the specificity and sensitivity are low because CA 19-9 is elevated in other diseases as well
Solution Approach 1:
The patent segments the diagnostic approach by introducing a panel of multiple tumor markers (CA 19-9, CEA, CA 72-4, and CFB) instead of relying on a single marker. Each marker targets different aspects of cancer pathology, allowing the system to distinguish pancreatic cancer from other diseases through combined analysis of marker patterns rather than individual marker levels
Solution Approach 2:
The patent creates a composite diagnostic profile by combining multiple tumor markers with different specificity characteristics. The combination of CA 19-9, CEA, CA 72-4, and CFB forms a composite diagnostic tool where the collective information from all markers provides higher diagnostic accuracy and disease specificity than any single marker alone
2Loss of time
If early diagnosis methods are not available, then pancreatic cancer progresses to late stages, but implementing comprehensive diagnostic methods increases complexity
Solution Approach 1:
The patent creates a universal diagnostic system that serves multiple functions: it can diagnose pancreatic cancer at various stages, differentiate from other gastrointestinal cancers, and provide prognostic information. The same multi-marker panel and analysis method can be applied across different clinical scenarios, reducing the need for multiple separate diagnostic tools and simplifying the overall diagnostic workflow despite the comprehensive nature of the approach
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The kit effectively distinguishes pancreatic cancer patients from healthy individuals and those with other diseases, particularly in early stages, providing improved sensitivity and specificity for early diagnosis and potentially increasing survival rates by enabling timely intervention.
Implementation Method 1
an antibody specifically binding to complement factor B protein
Implementation Method 2
an antibody specifically binding to carbohydrate antigen 19-9 protein
Data Source
AI summary
The present application relates to a kit for diagnosing pancreatic cancer, a method for providing information for diagnosing pancreatic cancer using the kit, and a method for diagnosing pancreatic cancer using same, wherein the kit includes an antibody specifically binding to complement factor B protein and an antibody specifically binding to carbohydrate antigen 19-9 protein. According to the present application, it is possible to provide a marker for diagnosing pancreatic cancer having enhanced sensitivity and specificity.